NCT04271813View on ClinicalTrials.gov

Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

September 30, 2023

Study Completion Date

February 29, 2024

Conditions
Colorectal CancerImmunotherapyAnlotinibSintilimabChemo-free TherapyFirst-line Treatment
Interventions
DRUG

Anlotinib plus Sintilimab

Anlotinib 12mg oral administration daily d1-d14, q3w; Sintilimab 200mg iv drop d1, q3w

Trial Locations (1)

Unknown

Department of Medical Oncology, Shanghai Changzheng Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Changzheng Hospital

OTHER

NCT04271813 - Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) | Biotech Hunter | Biotech Hunter